# A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

> **NCT06179446** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 157 (actual)

## Conditions studied

- Grippe
- Influenza
- Vaccines

## Interventions

- **BIOLOGICAL:** pdmFlu vaccine
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Licensed influenza vaccine

## Key facts

- **NCT ID:** NCT06179446
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-13
- **Primary completion:** 2025-09-23
- **Final completion:** 2025-09-23
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06179446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06179446, "A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06179446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*